Proteinuria Clinical Trial
Verified date | January 2002 |
Source | Southern Medical University, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely improve the long-term renal outcome in nondiabetic patients with proteinuria and chronic renal insufficiency. The second aim was to compare the long-term renal protection between benazepril and losartan at similar clinical setting.
Status | Terminated |
Enrollment | 0 |
Est. completion date | May 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Serum creatinine concentration of 1.5 to 5.0 mg per deciliter (133 to 442 µmol/L) 2. Creatinine clearance of 20 to 70 ml per minute per 1.73m2, with variations of less than 30 percent in the three months before screening evaluation 3. nondiabetic renal disease 4. Persistent heavier proteinuria (defined by urinary protein excretion of more than 1.0 g per day for three or more months without evidence of urinary tract infection or overt heart failure [a New York Heart Association class of ? or ?]) Exclusion Criteria: 1. Immediate need for dialysis 2. Treatment with corticosteroids, non steroidal anti-inflammatory drugs, or immunosuppressive drugs 3. Hyper-or hypokalemia (serum potassium concentration 5.6 mmol per liter or more,or 3.5 mmol per liter or less) 4. Renovascular disease 5. Myocardial infarction or cerebrovascular accident in the year preceding the trial 6. Connective-tissue disease; and obstructive uropathy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Renal Division, Nanfang Hospital,Southern Medical University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Southern Medical University, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary efficacy measure was the time to the first event of the composite endpoint of a doubling of the serum creatinine concentration, ESRD or death. | |||
Secondary | Secondary endpoints included changes in urinary protein excretion rate and the progression of renal disease assessed by creatinine clearance and glomerular filtration rate as calculated by Modification of Diet in Renal Disease equation-4. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Completed |
NCT05086549 -
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
|
||
Terminated |
NCT04051957 -
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02226055 -
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
|
N/A | |
Completed |
NCT02232763 -
Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria
|
Phase 3 | |
Terminated |
NCT02057523 -
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT00493727 -
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
|
N/A | |
Active, not recruiting |
NCT00565396 -
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Withdrawn |
NCT02882373 -
Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury
|
Phase 2 | |
Completed |
NCT02327403 -
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT01773382 -
The Effects of Weight Reduction in IgA Nephropathy
|
N/A | |
Completed |
NCT01029002 -
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Withdrawn |
NCT00541619 -
Sympathetic Overactivity in Essential Hypertension
|
N/A | |
Withdrawn |
NCT00392132 -
Impact of Screening Patients With HIV for Kidney Disease
|
||
Terminated |
NCT00001978 -
Determination of Kidney Function
|
||
Recruiting |
NCT05457283 -
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
|
Phase 3 | |
Completed |
NCT04874753 -
The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT02972346 -
Availability Study of ACTH to Treat Children SRNS/SDNS
|
N/A |